Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys

Amarendra Pegu,Ling Xu,Megan E DeMouth,Giulia Fabozzi,Kylie March,Cassandra G Almasri,Michelle D Cully,Keyun Wang,Eun Sung Yang,Joana Dias,Christine M Fennessey,Jason Hataye,Ronnie R Wei,Ercole Rao,Joseph P Casazza,Wanwisa Promsote,Mangaiarkarasi Asokan,Krisha McKee,Stephen D Schmidt,Xuejun Chen,Cuiping Liu,Wei Shi,Hui Geng,Kathryn E Foulds,Shing-Fen Kao,Amy Noe,Hui Li,George M Shaw,Tongqing Zhou,Constantinos Petrovas,John-Paul Todd,Brandon F Keele,Jeffrey D Lifson,Nicole A Doria-Rose,Richard A Koup,Zhi-Yong Yang,Gary J Nabel,John R Mascola,Megan E. DeMouth,Cassandra G. Almasri,Michelle D. Cully,Christine M. Fennessey,Ronnie R. Wei,Joseph P. Casazza,Stephen D. Schmidt,Kathryn E. Foulds,George M. Shaw,Brandon F. Keele,Jeffrey D. Lifson,Nicole A. Doria-Rose,Richard A. Koup,Zhi-yong Yang,Gary J. Nabel,John R. Mascola

DOI: https://doi.org/10.1016/j.celrep.2021.110199

IF: 8.8

2022-01-01

Cell Reports

Abstract:Broadly neutralizing antibodies (bNAbs) represent an alternative to drug therapy for the treatment of HIV-1 infection. Immunotherapy with single bNAbs often leads to emergence of escape variants, suggesting a potential benefit of combination bNAb therapy. Here, a trispecific bNAb reduces viremia 100- to 1000-fold in viremic SHIV-infected macaques. After treatment discontinuation, viremia rebounds transiently and returns to low levels, through CD8-mediated immune control. These viruses remain sensitive to the trispecific antibody, despite loss of sensitivity to one of the parental bNAbs. Similarly, the trispecific bNAb suppresses the emergence of resistance in viruses derived from HIV-1-infected subjects, in contrast to parental bNAbs. Trispecific HIV-1 neutralizing antibodies, therefore, mediate potent antiviral activity in vivo and may minimize the potential for immune escape.

cell biology